SQLite Web: event_store.db

Update row sig_50b098414ff0 in signals

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1130598/0001104659-26-043781.txt","as_of":"2026-04-16T02:08:52.472606+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1130598/0001104659-26-043781.txt","company":"Traws Pharma, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1130598/0001104659-26-043781.txt","article_chars":4999,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_2b23e8a8d1dbbe33","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1130598/0001104659-26-043781.txt","content_type":"text/plain","enriched_at":"2026-04-16T02:30:58.212005+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1130598/0001104659-26-043781.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1130598/0001104659-26-043781.txt","source_event_id":"evt_321ec1a3854b","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"6bd1fb9e9fa7221b","kind":"sec_filing","published_at":"20260415","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-15","2026-04-16","2025-12-31","Q1 2027"],"entities":[{"asset_class":"equity","name":"Traws Pharma, Inc.","relevance":"high","symbol":"TRAW","type":"issuer"},{"asset_class":"other","name":"SEC","relevance":"medium","symbol":"","type":"regulator"},{"asset_class":"other","name":"Exhibit 99.1","relevance":"high","symbol":"","type":"document"},{"asset_class":"other","name":"Tivoxavir marboxil","relevance":"medium","symbol":"","type":"product_candidate"},{"asset_class":"other","name":"Ratutrelvir","relevance":"medium","symbol":"","type":"product_candidate"},{"asset_class":"other","name":"PAXLOVID\u00ae","relevance":"low","symbol":"","type":"comparator"}],"event_type":"earnings","information_gaps":["The cleaned text does not include the full financial statements or specific financial metrics (e.g., revenue, net loss, cash balance) referenced by the earnings release; only Exhibit 99.1 headline/business highlights are shown.","The specific 8-K item(s) beyond Item 2.02/Item 7.01 are not detailed in the provided text (no other Item sections are shown).","The prior known state/delta versus earlier filings is not provided, so the exact change from a prior state cannot be determined from this signal alone."],"key_facts":["The filing is a Current Report on Form 8-K.","Item 2.02 incorporates by reference information provided under Item 7.01 (Regulation FD Disclosure) regarding an earnings release.","On April 15, 2026, Traws Pharma issued a press release announcing financial results for the fiscal year ended December 31, 2025.","The earnings release is furnished as Exhibit 99.1 to the Form 8-K.","Exhibit 99.1 text states: Tivoxavir marboxil is advancing toward a human influenza challenge trial as a once-monthly prophylactic agent.","Exhibit 99.1 text states: Ratutrelvir topline Phase 2a data show a differentiated profile versus PAXLOVID\u00ae in COVID patients, with good overall safety; final study analysis underway.","Exhibit 99.1 text states: Private financing of up to $60M (with $10M upfront) offering of common stock and milestone-based and three-year warrants completed on April 15, 2026 supporting operations into Q1 2027.","The filing includes standard forward-looking statements language and clarifies Exhibit 99.1 is furnished and not deemed filed for Section 18 purposes."],"numeric_claims":[{"label":"Financing amount (up to)","value":"$60M"},{"label":"Upfront portion","value":"$10M"},{"label":"Operations support through","value":"Q1 2027"},{"label":"Investor update call time","value":"4:30 PM"},{"label":"Investor update call date","value":"April 15, 2026"},{"label":"Fiscal year end","value":"December 31, 2025"}],"primary_claim":"On April 15, 2026, Traws Pharma issued a press release announcing its financial results for the fiscal year ended December 31, 2025, furnished as Exhibit 99.1 in its Form 8-K.","relevance_score":0.72,"sentiment":"mixed","source_quality":"high","summary":"Traws Pharma, Inc. filed a Form 8-K on April 15, 2026 furnishing an earnings release for the fiscal year ended December 31, 2025. The filing includes Exhibit 99.1 with business highlights and mentions financing of up to $60M completed on April 15, 2026.","topics":["Form 8-K","earnings release","fiscal year 2025 results","Regulation FD disclosure","Exhibit 99.1","financing","clinical development highlights"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 Traws Pharma, Inc. \u00b7 Filed 20260415","ticker":"TRAW","tickers":["TRAW"],"title":"TRAW filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1130598/0001104659-26-043781.txt"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel